Does TARCEVA Cause Malignant neoplasm progression? 29 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 29 reports of Malignant neoplasm progression have been filed in association with TARCEVA. This represents 4.7% of all adverse event reports for TARCEVA.
29
Reports of Malignant neoplasm progression with TARCEVA
4.7%
of all TARCEVA reports
19
Deaths
5
Hospitalizations
How Dangerous Is Malignant neoplasm progression From TARCEVA?
Of the 29 reports, 19 (65.5%) resulted in death, 5 (17.2%) required hospitalization, and 1 (3.4%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TARCEVA. However, 29 reports have been filed with the FAERS database.
What Other Side Effects Does TARCEVA Cause?
Death (274)
Rash (81)
Diarrhoea (65)
Incorrect dose administered (48)
Nausea (31)
Vomiting (25)
Disease progression (21)
Off label use (16)
Decreased appetite (15)
Dehydration (15)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which TARCEVA Alternatives Have Lower Malignant neoplasm progression Risk?
TARCEVA vs TARLATAMAB
TARCEVA vs TARLATAMAB-DLLE
TARCEVA vs TASIGNA
TARCEVA vs TASIMELTEON
TARCEVA vs TAVABOROLE